Autonomic eVects of selegiline: possible cardiovascular toxicity in Parkinson's disease

@inproceedings{Churchyard1997AutonomicEO,
  title={Autonomic eVects of selegiline: possible cardiovascular toxicity in Parkinson's disease},
  author={Andrew Churchyard and Christopher J. Mathias and P Boonkongchuen and Andrew J. Lees},
  year={1997}
}
Objectives—The United Kingdom Parkinson’s Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson’s disease randomised to receive selegiline (10 mg/day) and levodopa compared with those taking levodopa alone. Unwanted eVects of selegiline on cardiovascular regulation have been investigated as a potential cause for the unexpected mortality finding of the UKPDRG trial. Methods—The cardiovascular responses to a range of physiological stimuli, including… CONTINUE READING

Citations

Publications citing this paper.